Key result
6-gingerol reduces doxorubicin-induced CPK-MB elevation by ~58% in preclinical cardiotoxicity.
Why the study?
Doxorubicin has dose-related cardiotoxicity likely caused by oxidative stress from oxygen-centered free radicals, motivating investigation of antioxidant 6-gingerol's protective effect.
Does 6-gingerol prevent doxorubicin-induced cardiotoxicity in mice?
Does 6-gingerol prevent doxorubicin-induced cardiotoxicity in mice?
Effect estimate: 58% reduction
Absolute Event Rate: 111% vs 260.2%
p-value: p=< 0.05
6-gingerol pretreatment significantly ameliorates doxorubicin-induced cardiotoxicity in a mouse model, suggesting potential as a cardioprotective agent.
May attenuate DOX cardiotoxicity in animal models; leaves open clinical translation and requires prospective human trials.
Doxorubicin (DOX) has a wide spectrum of antitumor activity with dose-related cardiotoxicity as a major side effect.This cardiotoxicity has been suggested to result from enhanced oxidative stress caused by oxygen centered free radicals.The present study was performed to investigate the influence of the antioxidant 6-gingerol on cardiotoxicity induced by doxorubicin (DOX).A single dose of DOX (20 mg/kg i.p.) induced myocardial toxicity after 48 hrs, manifested biochemically by a significant elevation in the following serum enzymes activities: creatine phosphokinase (E.C.2.7.3.2),lactate dehydrogenase (E.C.1.1.1.27),aspartate transaminase (E.C.2.6.1.1)and serum cardiac isoenzyme creatine phosphokinase (MB).Administration of 6-gingerol (10 mg/kg/day p.o.) in drinking water starting 5 days before and continuing during the experimental period significantly ameliorated myocardial toxicity induced by DOX.The amelioration of cardiotoxicity was evidenced by significant reductions in serum enzymes activities and cardiac isoenzyme.The current data support 6-gingerol as a potentially selective cardioprotective agent, against cardiotoxicity induced by DOX and it may therefore improve the therapeutic index of DOX.
No takes yet. Share an insight, caveat, or question.
Mansour et al. (2008) studied Doxorubicin-induced cardiotoxicity (n=60). 6-gingerol vs. Doxorubicin alone (20 mg/kg i.p.) was evaluated on Serum cardiac isoenzyme CPK-MB activity at 48 hours (U/L) (58% reduction, p=< 0.05). Administration of 6-gingerol significantly ameliorated doxorubicin-induced myocardial toxicity, evidenced by a 58% reduction in cardiac isoenzyme CPK-MB activity at 48 hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: